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Abstract
Background: Glucose-6-phosphate dehydrogenase deficiency poses a significant impediment to primaquine use
for the elimination of liver stage infection with Plasmodium vivax and for gametocyte clearance, because of the risk
of life-threatening haemolytic anaemia that can occur in G6PD deficient patients. Although a range of methods for
screening G6PD deficiency have been described, almost all require skilled personnel, expensive laboratory
equipment, freshly collected blood, and are time consuming; factors that render them unsuitable for mass-
screening purposes.
Methods: A published WST8/1-methoxy PMS method was adapted to assay G6PD activity in a 96-well format
using dried blood spots, and used it to undertake population screening within a malaria survey undertaken in
Isabel Province, Solomon Islands. The assay results were compared to a biochemical test and a recently marketed
rapid diagnostic test.
Results: Comparative testing with biochemical and rapid diagnostic test indicated that results obtained by filter
paper assay were accurate providing that blood spots were assayed within 5 days when stored at ambient
temperature and 10 days when stored at 4 degrees. Screening of 8541 people from 41 villages in Isabel Province,
Solomon Islands revealed the prevalence of G6PD deficiency as defined by enzyme activity < 30% of normal
control was 20.3% and a prevalence of severe deficiency that would predispose to primaquine-induced hemolysis
(WHO Class I-II) of 6.9%.
Conclusions: The assay enabled simple and quick semi-quantitative population screening in a malaria-endemic
region. The study indicated a high prevalence of G6PD deficiency in Isabel Province and highlights the critical
need to consider G6PD deficiency in the context of P. vivax malaria elimination strategies in Solomon Islands,
particularly in light of the potential role of primaquine mass drug administration.
Background
Glucose-6-phosphaste dehydrogenase (G6PD) is an
important enzyme in cellular metabolism in the first
and rate-limiting step of pentose-phosphate pathway.
Among the functions of this pathway is the protection
of cells from oxidative stress, through its role in conver-
sion of NADP to NADPH, thereby replenishing the
levels of reduced glutathione. As erythrocytes lack other
detoxifying enzymes, people with G6PD deficiency are
susceptible to oxidative stress in their red blood cells.
The G6PD gene is located on the X chromosome, and
as a result deficiencies show X-linked inheritance,
whereby a higher proportion of males suffers from the
deficiency. A wide array of genetic variants has been
identified, which confer differing phenotypes. These
include the well characterised G6PDA
- and G6PD Medi-
terranean variants [1,2].
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iant of the G6PD gene, with disproportionately higher
prevalence observed in tropical regions [1-3]. The fact
that the prevalence of G6PD deficiency correlates with
endemicity for malaria had lead to the hypotheses that
G6PD deficiency may be result of natural selection con-
ferring protection against malaria infection [2-5]. How-
ever, studies have indicated that this protection may
only occurs with certain G6PD variants, and that differ-
ing level of protection are likely to be seen in hemizy-
gous males, homozygous and heterozygous females
[1,4,6-8].
With the exception of rare sporadic WHO class I indi-
viduals, most G6PD deficient individuals are asympto-
matic [1,2]. However, specific triggers such as ingestion
of certain foods (e.g. fava beans), exposure to oxidative
drugs, and infection can cause haemolytic anaemia, and
in severe cases haemolysis sufficiently severe to require
blood transfusion. Such adverse events are generally
confined to individuals with G6PD activity < 10% of
normal (WHO Class II).
The anti-malarial drugs primaquine, dapsone, and the
experimental drug tafenoquine are oxidative anti-malar-
ials and can cause haemolytic anaemia. Primaquine is
the most important of these, being the only approved
anti-malarial that can be used to eliminate Plasmodium
vivax hypnozoites and Plasmodium falciparum gameto-
cytes. As a result there is increasing public health con-
cern with implementation of malaria elimination
initiative worldwide using mass drug treatment pro-
grammes [9-11]. Studies of tolerance of primaquine
undertaken in G6PD deficient individuals have sug-
gested that a course of lower dosage treatment such as
0.75 mg/kg/week for eight weeks or 15 mg/day for 14
days compared with the standard 30 mg/day for 14 days
may be safe [10,12,13]. However, given the wide genetic
and phenotypic variability of G6PD, it is considered a
priority to undertake phenotypic and genetic analysis,
and perhaps a carefully controlled tolerance trial on dif-
ferent populations where primaquine MDA is being
considered for elimination [14,15].
Direct testing of the enzymatic activity of G6PD on a
freshly collected blood sample is the most widely used
diagnostic method for diagnosis of deficiency. Methods
used include older tests such as brilliant cresyl blue
decolourization test and methaemoglobin reduction test
[16,17]. The methodology recommended by the Interna-
tional Committee for Standardisation in Haematology is
the NADPH fluorescent spot test, which requires a UV
lamp [18,19]. These method all have shortcomings that
limit their use in mass-screening or in field settings
[18]. Other methods that do not require UV lamp have
been used for screening studies include the ring method
and Sephadex gel MTT-PMS method [20-24]. These
methods are also used as a diagnostic test prior to
primaquine treatment in larger hospitals and health cen-
tres in developing countries, where the necessary facil-
ities and equipment are available. Other metods that
have been described for tesitng include cytochemical
assays [25], and DNA sequence analysis of the G6PD
gene. The former has the advantage of being a reliable
method for detection of hemizygous deficient males,
homozygous deficient females, or heterozygous deficient
females because the G6PD status of individual erythro-
cytes is tested [26]. DNA sequence analysis reqiures
analysis of the whole gene which spans 18kB of genomic
sequence [1]. However, all of these tests suffer from
limitations that inhibit their utility for in-field mass-
screening purposes, due to factors such as technical
expertise required, expense, duration of test procedure,
sensitivity of reagents to light and heat, low detection
threshold, or relatively low throughput capacity [22,24].
A new enzymatic method was described by Tantular
a n dK a w a m o t ot h a tu t i l i z e sat e r a z o l i u ms a l tk n o w na s
WST8, and a less light-sensitive form of the PMS hydro-
gen carrier, called 1-methoxy PMS [27]. The reduced
light sensitivity and the colourimetric nature (both qua-
litative and quantitative) of this method, and the possibi-
lity of using it with dried bloodspot make it potentially
more suitable for field use [28]. In this manuscript a
method for screening for mass screening for G6PD defi-
ciencey is described. It is modified from the WST8
method and was optimizied to a 96-well plate format
and using dried blood spots with internal standards as
controls. The present study reports the evaluation of
this method for in-field mass-screening of G6PD to
determine the prevalence of G6PD deficiency in Isabel
Province, Solomon Island.
Methods
Population and sample collection
This study took place in October 2009 as part of a com-
prehensive baseline malaria survey conducted to inform
the implementation of the national malaria control and
elimination programme in Solomon Islands. The survey
was undertaken by the Vector Borne Disease Control Pro-
gramme (VBDCP) in collaboration with the Australian
government funded Pacific Malaria Initiative Support Cen-
tre (PacMISC; a Brisbane-based consortium between the
School of Population Health at the University of Queens-
land; the Queensland Institute of Medical Research; and
the Australian Army Malaria Institute). The survey was
undertaken in Isabel Province, which consists of a main
island, Santa Isabel, and many other smaller surrounding
islands. A total of 41 villages in Isabel Province, were vis-
ited over the course of 28 days. Samples were collected,
after informed consent, from 8541 males and females of
all ages. Isabel is predominantly populated with people of
Kuwahata et al. Malaria Journal 2010, 9:223
http://www.malariajournal.com/content/9/1/223
Page 2 of 10Melanesian ethnicity and therefore specific ethnicity data
was not collected.
Blood spots were collected from finger-prick blood
onto 3 MM filter paper (Whatman) and were dried at
ambient temperature. The dried blood spots were stored
individually in zip-lock bags containing silica desiccant
beads and refrigerated (4-8°C) whenever possible. All
samples were assayed within 10 days from collection.
Assay mixes and controls
A concentrated assay mix was prepared beforehand in
Australia and frozen aliquots transported to Isabel Pro-
vince. The mix contained 50 mM glucose-6-phosphate
(Oriental Yeast Co. Japan), 4 mM NADP (Merck Pty
Ltd.), 1 M Tris-HCl pH7.2-7.5 and 100 mM MgCl2
(Sigma-Aldrich). A second mix was also prepared to
serve as substrate negative control. This control mix
lacked glucose-6-phosphate and NADP. WST-8 -1-
methoxyPMS was obtained from Dojindo Laboratoreis
(Japan). Working assay mix was prepared just prior to
setting up each assay. For each 96-well plate 0.5 mL of
concentrated mix and 0.5 mL of WST8 reagent were
added to 19 mL of water. A no-substrate control mix
was also prepared with 1 mL water, 26.3 μL concen-
trated no-substrate mix, and 26.3 μL WST8 reagent.
To calibrate the assay panel of reference control sam-
ples with defined G6PD activity were prepared. A com-
mercial standard reagent of known normal G6PD
activity (G6PD control Normal, Trinity Biotech) that
consists of lyophylised G6PD in human red cell hemoly-
sate base with stabilisers and preservatives [29] was used
to create a panel of internal controls that were used in
each assay. These consisted of normal, moderate (WHO
Class III deficient ~30% enzyme activity), and severe
(WHO Class II deficient ~10% enzyme activity) defi-
ciency, and no enzyme (0%) control. To prepare moder-
ate and severe controls, the reference normal G6PD
control sample was diluted with human blood that had
been rendered to have no G6PD activity by heating to
50°C for 20 minutes; for the no-enzyme control only the
inactivated blood was used. Aliquots of these control
samples were frozen until required. G6PD activity was
classified using a slightly modified version of a pre-
viously published reference range [2], < 10% activity
(WHO Class I-II) was classified as severe deficiency,
while < 30% enzyme activity was classified as moderate
deficiency.
G6PD assay
On each day when the assays were undertaken a set of
controls (normal, moderately deficient, severely defi-
cient, no-enzyme) were taken and spotted onto 3 MM
filter paper. A single
1/16 inch diameter disc (FISKARS
Hand Punch) was punched out from each blood-spot
sample, and placed in a single well of a 96-well flat bot-
tom microplate (Greiner Bio-One). Control spots and an
extra bloodspot for no-substrate control were also
punched and placed in allocated wells. One well
remained empty and served as a “no sample” negative
control. 200 μL of working assay was then pipetted and
mixed into each well except the substrate negative con-
trol well, into which 200 μL of no-substrate assay mix
was added. Plates were then incubated for 2 hours at
ambient temperature.
96 well plates were first inspected by eye, and then
absorbance quantified in a microplate reader (Chromate
4300, Awareness Technology) at OD450-595 .N o r m a l
G6PD activity is indicated by dark yellow to orange col-
ouration, while severe and moderate deficiency appear-
ing as almost colourless, and faintly yellow colouration
respectively (Figure 1). Although for the purpose of this
study only deficient (severe or moderate)/normal status
were recorded, it was possible to distinguish intermedi-
a t ef r o mn o r m a la c t i v i t yb yt heir intermediate yellow
colouration and absorbance.
Preliminary experiments
To determine limitations of the storage condition of
bloodspots and assay mixes two separate pilot experi-
ments were undertaken prior to the field survey. The
storage stability of G6PD enzyme as bloodspots were
assessed at 4°C, 25°C and 37°C over a period of two
weeks using bloodspots with known G6PD activity.
Bloodspots used in the experiment were manually
Control 1 –Normal 
Control 2 – Moderately deficient 
Control 3 – Severely Deficient 
Control 4 – Severely Deficient 
Deficient sample 
Figure 1 Appearance of assay plate wells for testing of G6PD
activity from dried blood spots. The distinct yellow colour (first
well) indicates a sample with normal G6PD activity, the well with
pale yellow colour (second well) represents a sample with moderate
deficiency, and the remaining three almost colourless wells are
indicative of severe deficiency.
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cial normal G6PD control (5%, 10%, 15%, 25%, 50%,
complete normal). These spots were dried and stored in
zip-lock bags containing silica gel until tested. In a sepa-
rate preliminary experiment the performance of stored
assay mixes was also evaluated. Assay mixes were pre-
pared as a complete mix of all required reagents, then
stored at ambient temperature in the dark for 4 days, 1
week, 2 weeks, 3 weeks and 4 weeks, and were used to
assay control bloodspots.
Comparison of WST8 screening assay with other assays
for G6PD
To evaluate the WST8 assay as a screening method,
blood was collected by venipuncture into EDTA vacutai-
ners from 20 individuals at Buala Hospital in Isabel
Isalnd. These blood samples were tested using the
WST8 assay, an FDA-approved G6PD rapid diagnostic
test (BinaxNow, Inverness Medical), and by quantitative
biochemical testing using a commercial assay kit (Tri-
nity Biotech) at the Pathology department of Royal Bris-
bane and Women Hospital, Brisbane, Australia within
four days of collection. To control for possible loss of
enzyme activity in collected blood stored until testing,
blood samples from two investigators with known levels
of G6PD activity were collected at the same time as the
clinical sample.
Ethics
Ethical approval to undertake the malaria survey includ-
ing the G6PD prevalence survey was obtained from the
Solomon Islands Health and Ethics Committee; the
Research Ethics Committees of the University of
Queensland and the Queensland Institute of Medical
Research; and from the Australian Defence Human
Research Ethics Committee.
Statistical analysis
Chi-square and odds ratio were used to test for any sig-
nificant differences in prevalence of G6PD deficiency
between males and females. Geographical Information
System (GIS) data, including the village point informa-
tion, was used in ArcGIS software (ESRI) to assess for
spatial autocorrelation using Moran’s I statistics. Mor-
an’s I value of +1 represents correlation, -1 represents
dispersion and 0 indicates a random spatial pattern.
Spatial cluster analysis using SaTScan (v7.0.3) was also
performed to explore for evidence of clustering of G6PD
deficiency. Standardized residuals were calculated using
chi-square analysis to assess for differences in preva-
lence of G6PD deficiency between villages to identify
villages that may have shown an unexpectedly higher
proportion of moderate deficiency.
Results
Evaluation of bloodspot and assay mix storage
Bloodspots stored at 4°C, 25°C and 37°C were assayed
on Day 1, 5, 10 and 14 to determine its effect on
enzyme degradation and the resulting reduced G6PD
activity. The Day 1 assay indicated that only bloodspots
with known enzyme activity of < 10% tested deficient,
with no differences apparent between blood spots stored
at different temperatures. (Table 1). However, the test
results at Day 5 indicated that only those bloodspots
stored at 4°C were equivalent to those obtained on Day
1. At 25°C and 37°C those with original activity of 15%
were being judged as deficient (< 10%), indicating that ≥
5% of activity was lost. As storage duration and tem-
perature increased, bloodspots with original activity of
15-50% tested deficient in the assay indicating ≥ 5-40%
loss of activity. Our experiment showed reduced activity
of ~5% in bloodspots stored for 10 days at 4°C, and for
5 days at 25°C and 37°C, a finding that indicates that
bloodspots could be stored within these limitations and
still yield reliable results.
The stability of assay mixes was likewise evaluated
(Figure 2). Assay mix stored up to two weeks at ambient
temperature showed relatively stable assay performance
compared to freshly prepared assay mix. Assay mix
Table 1 The effect of storage temperature and duration on dried blood spot estimation of GPD enzyme activity
Storage temperature Baseline G6PD enzyme activity (%) that results in a sample testing severely deficient
(<10% activity) at the designated storage temperature and duration
Decay in enzyme activity
Day 1 Day 5 Day 10 Day 14
4°C 10% 10% 15% 15% ~ 5% by Day 10
25°C 10% 15% 25% 25% ~ 5% by Day 5
~ 15% by Day 10
37°C 10% 15% 25% 50% ~ 5% by Day 5
~ 15% by Day 10
~ 40% by Day 14
The reliability of G6PD assays on blood spots stored for different times at different temperatures was assessed with bloodspots containing differing amount of
reference G6PD enzyme activity. The table shows the % enzyme activity that tested as deficient (≤ 10% activity) at days 1, 5, 10 and 14 when stored at 4°C, 25°C
and 37°C. The decay in enzyme activity represents the difference between the original enzyme activity and the activity when retested.
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rant performance.
Assay validation
Testing was undertaken on 20 individuals at Buala Hos-
pital using three methods: the WST8 assay, the FDA-
approved RDT BinaxNow, and a quantitative enzymatic
assay undertaken at the Pathology department, Royal
Brisbane and Women’s Hospital in Australia a few days
later. Table 2 displays the results from the three tests. Of
the 20 individuals, all three tests indicated that 14 people
showed normal activity. Definitive enzyme testing and
WST8 assay identified the same five deficient individuals
and one with intermediate activity. The BinaxNow RDT
identified the same six individuals as deficient, but was
unable to distinguish the individual with intermediate
enzyme activity from the deficient individuals.
G6PD deficiency prevalence
Results from 8,541 individuals were analysed, comprising
3,880 males and 4,636 females. The G6PD deficiency pre-
valence is summarized in Table 3. Analysis revealed that
overall 1,731 individuals (20.3%) showed G6PD deficiency,
and of these 590 individuals (6.9%) were observed to have
severe deficiency (< 10% of normal enzyme activity).
While there was only a slight preponderance of overall
deficiency among males, with deficiency of 21.7% (n =
843) and 19.1% (n = 886) respectively for males and
females, there was a significantly higher prevalence of
severe deficiency among males compared to females,
10.9% (n = 421) and 3.6% (n = 168) respectively (p <
0.0001, OR = 3.2, 95% CI 2.7-3.9). This gender specific
difference is apparent on inspection of a graphical
representation of the distribution of activity percentage
relative to normal G6PD activity (Figure 3).
Prevalence by village
G6PD deficiency was mapped using GIS data obtained
d u r i n gt h es u r v e ya n df r o mt h e1 9 9 9c e n s u sb yt h e
Solomon Island Ministry of Lands, Housing and Survey
(Figure 4). Prevalence of ≥ 10% severe deficiency was
observed in Jejevo, Susubona, Hovikoilo and Kolosori
West, Sigana, Popoheo, Thithiro. Although severe defi-
ciency was not observed in Kolopakisa or Tusa, the
number of people sampled from these villages was small.
The village-wise G6PD deficiency prevalence data was
assessed for spatial autocorrelation using Moran’sIs t a -
tistics, and for spatial cluster using SaTScan (v7.0.3).
Moran’s I values obtained for severe deficiency in
females, males and both genders combined were close to
0.00 and p values were greater than 0.10 (Table 4). This
i n d i c a t e dt h a tp r e v a l e n c eo fs e v e r eG 6 P Dd e f i c i e n c yi s
neither correlated nor dispersed, and that it is randomly
distributed across Isabel Province. Spatial cluster analysis
scan was undertaken to identify clusters with high rates
of severe deficiency using Poisson model. This analysis
identified two clusters for severe G6PD deficiency in
females. The first cluster was located on the south-east-
ern area consisting of Hovikoilo, Kolosori West, Sogo-
lona, and Popoheo (p = 0.001), and the second cluster
included Sepi and Sigana (p = 0.001) which are located
on the southern tip of Isabel Island (Figure 5).
Discussion
Various screening methodologies used to assay G6PD
activity require laborious techniques and equipment
Figure 2 Assay performance with assay mix stored for up to 4 weeks. Absorbance readings from bloodspot samples with known levels of
G6PD using assay mixes stored for varying durations at ambient temperature. Each line represents assay results with a different assay mix.
Uniform assay performance was observed with assay mixes stored for up to 2 weeks, but abnormal or degrading performance was observed in
those stored for 3 and 4 weeks.
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photometers, microscopes or DNA sequencing appara-
tus. Without significant financial, infrastructural, and
technical support many of these methods are not suita-
ble for field-based mass-scr e e n i n ga si sl i k e l yt ob e
required to support primaquine mass drug administra-
tion, implemented as part of a malaria elimination pro-
gramme. To develop an assay more suitable for this
purpose, we have adapted an existing published metho-
dology for mass-screening utilizing dried filter paper
bloodspots on a 96-well microtitre plate which enables
assaying G6PD of large numbers of blood spots in
places with limited laboratory facilities. To improve
assay robustness we developed a range of controls suita-
ble for calibration of results in a field setting.
Evaluation of the performance of this semi-quantita-
tive G6PD assay using blood from 20 individuals from
Buala village in Isabel Province, Solomon Islands against
an FDA-approved G6PD RDT and quantitative bio-
chemical testing indicated high level of agreement, and
confirmed the ability of this G6PD assay to identify defi-
cient individuals. Interestingly, it was also possible to
identify the female subject who showed mild deficiency
(most likely a heterozygote) using the assay. However,
confirming her status would require supplemental test-
ing such as a cytochemical assay [26].
This G6PD deficiency study took place in conjunction
with a malaria survey which already required sampling
of finger-prick blood for microscopy and filter paper for
PCR. Use of finger-prick blood has been found to be
more acceptable in various cultures and communities
around the world, and allows for less-laborious collec-
tion of large number of samples [30,31]. Additionally,
blood collected on filter paper can be stored in bulk and
p r o c e s s e d .T h eG 6 P Dd e f i c i e n c ys u r v e yt h e r e f o r ew a s
easily integrated into the broader malaria survey. Future
malaria surveys that are conducted to monitor transmis-
sions could include this assay at little overall additional
cost and resource requirement.
This study has indicated that G6PD deficiency is pre-
sent in Isabel Province, with a prevalence of severe defi-
ciency of 6.9%. As expected, the prevalence of severe
deficiency was significantly higher in males (10.9%) than
in females (3.6%) (p < 0.0001). Although the prevalence
of severe deficiency was prominently higher in males,
when looking at moderate deficiency alone, slightly
higher prevalence was found in females than males
(15.5%, vs. 10.9%). This could be due to a predominating
G6PD variant that phenotypically expresses a severe
form of deficiency resulting in large number of hetero-
zygous females but fewer males present with moderate
activity of G6PD. Heterozygous females are difficult to
identify using enzymatic tests, as they can have vastly
different enzyme levels depending on the variant and
level of mosaicism [32,33]. It is not possible to distin-
guish between the homozygous and heterozygous
females in the population or to determine the G6PD
variant without undertaking cytochemical or molecular
analysis [7,34].
The overall prevalence of severe deficiency of 6.9%
(10.9% in males) is similar to prevalence levels reported
in other studies that have been undertaken in the South-
west Pacific, such as in Vanuatu (6.8% - 7.4%) [5,35]. An
earlier study conducted in Solomon Islands included a
small group of people from Isabel Province, and found a
Table 2 Comparison of G6PD test results using different
assay methods
Number Gender WST8 RDT
(BinaxNow)
RBWH Clinical
Pathology
laboratory
1 M Deficient Deficient 0.6
2 M Deficient Deficient 0.6
3 M Deficient Deficient 0.6
4 M Deficient Deficient 0.3
5 M Deficient Deficient 0.5
6 F Intermediate Deficient 7.9
7 F Normal Normal 13.8
8 F Normal Normal 12.9
9 F Normal Normal 13.6
10 M Normal Normal 13.4
11 F Normal Normal 13.6
12 F Normal Normal 14.3
13 M Normal Normal 12.9
14 F Normal Normal 12.2
15 F Normal Normal 13.4
16 F Normal Normal 12.7
17 M Normal Normal 15.6
18 M Normal Normal 15
19 M Normal Normal 10
20 F Normal Normal 13.2
Control
1
M Normal Normal 15.2
Control
2
F Normal Normal 12.8
Pathology testing 9-20 U/gHb is classified as Normal.
Table 3 G6PD deficiency prevalence in Isabel Province
and prevalence by gender (n(%))
Total (%) Male (%) Female (%)
Samples tested 8,541 3,880 (45.6) 4,636 (54.4)
Normal 6,810 (79.7) 3,037 (89.9) 3,750 (80.9)
Total deficient
† 1,731(20.3) 843 (21.7) 886 (19.1)
Severe deficient
†† 590 (6.9) 421 (10.9) 168 (3.6)
Moderate deficient
††† 1,141 (13.4) 422 (10.9) 717 (15.5)
† < 30% normal enzyme activity
†† < 10% normal enzyme activity
††† 10-30% normal enzyme activity
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cies [36]. Our study also showed an average prevalence
of 20.27% (21.73% in males) including moderate defi-
ciencies. Studies in areas of Papua New Guinea and
New Britain have reported prevalence of G6PD defi-
ciency ranging from 0-53% and 0.8-23% respectively
[37,38]. In the study reported by Gorman and Kidman
[37], the variation in prevalence was found to correlate
with the altitude, suggesting a role of selective advantage
due to protection from malaria as transmission follows
similar patterns [37]. Furthermore, different linguistic
groups from the same regions showed different preva-
lence of G6PD deficiency. Studies from Papua New Gui-
nea suggest that separate andd i s t i n c te v o l u t i o no fr e d
blood cell traits exist due to combination of selective
advantage and relative isolation of populations [38-40].
Considering the existence of the very large number of
linguistic groups, and that many of the islands present
dramatic topographic barriers, differences in intra- and
inter-island prevalence in Vanuatu and Solomon Islands
could be expected.
While several villages were identified as having severe
deficiency prevalence of over 10%, spatial autocorrela-
tion of village-wise prevalence data from Isabel Province
showed that there is no spatial pattern of neither corre-
lation or dispersion of severe deficiency prevalence. Vil-
lage-wise prevalence of G6PD severe deficiency showed
a random spatial pattern. However, spatial cluster analy-
sis with SaTScan revealed two clustering regions of
G6PD severe deficiency prevalence in females. Although
clustering of deficiency in females may imply that some
consanguinity may exist within these villages, the overall
spatial analysis data maybe suggesting that there has
been ample gene flow across villages (inter-village mar-
riages) or that there has not been isolated exposure of
confined selection pressure needed to establish distinct
patterns of G6PD deficiency prevalence in Isabel Pro-
vince. However, further investigation is needed to
Figure 3 Distribution of G6PD activity in Isabel Island by gender. OD measures were converted to % activity relative to normal control and
were graphed to visualise any difference in distribution pattern of G6PD activity between males and females.
Figure 4 Map of G6PD deficiency prevalence in Isabel Province.
G6PD deficiency prevalence in villages was mapped to compare
prevalence among villages. High severe deficiency (> 10%) were
observed in Susubona, Jejevo, Hovikoilo, Kolosori West, Sigana,
Popoheo and Thithiro.
Table 4 Spatial autocorrelation (Moran’s I statistics) of
village-wise severe G6PD deficiency
Females Males Combined
Moran’sI 0.18 0.32 0.19
Z score 0.32 0.55 0.35
P > 0.10 > 0.10 > 0.10
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and genotyping of the G6PD gene from this population
may be able to shed light on this.
In several villages a significantly higher total preva-
lence of G6PD deficiency was observed (30-45%). How-
ever, whether this represents a higher prevalence of
deficiency or is due to other factors such as suboptimal
assay performance in very wet conditions cannot be
determined without repeating the tests in these villages.
Bloodspots were collected from these villages on rainy
and particularly humid days, when it was observed that
blood spots did not saturate through the filter paper,
but rather smeared across a larger surface area. It is
possible that this effect was due to filter papers becom-
ing damp before blood samples were taken. The conse-
quence of using such bloodspots is that the volume of
blood in each punched spot is lower than a completely
saturated bloodspot, thereby impeding comparison
against the controls. Furthermore, samples collected on
such days were also difficult to dry. Drying is an impor-
tant step, especially for the storage and consistent elu-
tion for the assay [30,41]. Both of these considerations
m a yh a v ec o n f o u n d e dm e a s u rement of G6PD activity,
and have led to a greater proportion of individuals
showing lower normal activity or moderate deficiency.
To minimize these issues, it is recommended that filter
paper be stored in zip-lock bags containing silica gel
desiccants before being used for blood collection, and
perhaps change of silica gel desiccants frequently after
collection for samples that were not able to be dried
sufficiently due to wet weather conditions.
In this respect, the red cell volume is known to affect
the outcome of assays for G6PD activity [42]. Formal
testing of G6PD activity is accompanied by a haemato-
crit/haemoglobin testing for this reason. The effect of
differing levels of haematocrit on this assay was not
explored in this study, and it may represent a factor that
requires consideration in future studies.
Aside from the potential problems discussed above the
assay performed well, with the majority of samples (n =
8,541) collected and processed in 28 days by just by 1
or 2 operators. In this survey, storage conditions were
not constrained and assay mixes and reagents were able
to be stored at optimal storage temperatures. However,
in preliminary experiments it was observed that pre-
pared mixes can be used up to two weeks when stored
at ambient temperature in the dark. This may allow
assays to be done during a two-week period in isolated
field settings where access to refrigerator/freezer is lim-
ited. The preliminary experiments also showed that
bloodspots can be stored for up to 10 days if stored at
4°C or up to 5 days at ambient temperature with only
about 5% reduction in activity. Therefore, it would be
possible to undertake batch processing if there is a sui-
table number of operators to process large number of
samples at a time.
Conclusions
With the progress of worldwide efforts to eliminate
malaria, G6PD deficiency and mass drug administration
with primaquine has assumed increasing importance to
countries affected by Plasmodium vivax infection. If
implemented safely and effectively, MDA could be a
powerful strategy as a step towards elimination [11,43].
To assess the prospect of primaquine MDA the preva-
lence of G6PD deficiencies in areas of interest must be
estimated. In this study, the applicability of a filter paper
mass-screening assay to provide prevalence of G6PD
deficiency in Isabel Province was evaluated. This study
showed that it was possible to undertake a large-scale
mass screening of G6PD deficiency in the field using the
filter paper assay in order to assess prevalence of the
deficiency. Results of the survey indicate that G6PD
deficiency is prevalent in Isabel Province, and as a con-
sequence this must be taken into consideration with any
future planning of strategies for malaria elimination in
this Province.
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